CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Complementing this line of evidence, a more recent study using single-cell gene expression analysis in conjunction with immunophenotypic screening revealed a distinct signature of Lin-CD34+CD38−/lowCD45RA−cKIT−CD26+ as being associated with a particular CML LSC compartment that is relatively insensitive to tyrosine kinase inhibitor (TKI) treatment [46].